SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chadwick E, et al. Safety and antiviral activity of fosamprenavir/ritonavir once daily regimens in HIV-infected paediatric subjects ages 2 to 18 years (48-week interim data, study APV20003). In 14th Conference on Retroviruses and Opportunistic Infections 2007. Los Angeles.
  • 2
    Cotton M, et al. Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-positive four weeks to <two year-old children (48-week data, study APV20002, a prospective, open-label, multi-centre, 48-week cohort study). In 19th International AIDS Conference (IAC) 2012. Washington, DC. Abstract TUAB0202.
  • 3
    Voronin E, et al. Pharmacokinetics, safety and antiviral activity of fosamprenavir-containing regimens in HIV-positive 2 to 18 year-old children (48-week data, Study APV29005, a prospective, open-label, multi-centre, 48-week cohort study). in 19th International AIDS Conference (IAC). 2012. Washington, DC. Abstract no. MOPE049.
  • 4
    GSK Clinical Study Register, Available at: http://www.gsk-clinicalstudyregister.com/index.jsp.
  • 5
    Palladino C, et al., Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J 2010; 29(6): 563566.
  • 6
    de Wolf F, et al., Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. Clinical Investigation 2012; 2: 255264.
  • 7
    Division of AIDS, Division of AIDS table for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004; clarification August 2009, Bethesda, MD: National Institutes of Health.
  • 8
    Anon, Antiretroviral treatment of HIV infection—updated Swedish recommendations 2009. Information from the Swedish Medical Product Agency, 2011; 3: 835 (Article in Swedish).
  • 9
    Giaquinto C, et al., Italian consensus statement on paediatric HIV infection. Infection 2010; 38(4): 301319.
  • 10
    Welch S, et al., PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10(10): 591613.
  • 11
    Calmy A, et al., Clinical update: adverse effects of antiretroviral therapy. Lancet 2007; 370(9581): 1214.
  • 12
    Torres H.A., Arduino R.C., Fosamprenavir calcium plus ritonavir for HIV infection. Expert Rev Anti Infect Ther 2007; 5(3): 349363.